A Prospective, Observational, Post-Authorisation Efficacy Study to Assess Long-term Effectiveness of Risdiplam in Patients with Genetically Confirmed 5q SMA

29/06/2022
22/04/2025
EU PAS number:
EUPAS47916
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Prot BN43428 risdiplam v1, Published Output-1_Redacted

English (1.94 MB - PDF) View document
Updated protocol

Prot_BN43428_risdiplam_v2_12Dec2024_Redacted.pdf

First published: 15/04/2025
English (1.37 MB - PDF) View document
Study results
Study report
Other information